58 related articles for article (PubMed ID: 7567946)
21. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
22. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
[TBL] [Abstract][Full Text] [Related]
23. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
24. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma.
Ito K; Sasano H; Matsunaga G; Sato S; Yajima A; Nasim S; Garret CT
J Pathol; 1997 Nov; 183(3):318-24. PubMed ID: 9422988
[TBL] [Abstract][Full Text] [Related]
25. Overexpression and mutation of p53 in endometrial carcinoma.
Kohler MF; Berchuck A; Davidoff AM; Humphrey PA; Dodge RK; Iglehart JD; Soper JT; Clarke-Pearson DL; Bast RC; Marks JR
Cancer Res; 1992 Mar; 52(6):1622-7. PubMed ID: 1540970
[TBL] [Abstract][Full Text] [Related]
26. Analysis of p53 abnormalities in endoscopic gastric biopsies.
Imatani A; Sasano H; Asaki S; Toyota T; Saito M; Masuda T; Nagura H
Anticancer Res; 1996; 16(4A):2049-56. PubMed ID: 8712741
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma.
Caduff RF; Johnston CM; Svoboda-Newman SM; Poy EL; Merajver SD; Frank TS
Am J Pathol; 1996 May; 148(5):1671-8. PubMed ID: 8623934
[TBL] [Abstract][Full Text] [Related]
28. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China.
Gao H; Wang LD; Zhou Q; Hong JY; Huang TY; Yang CS
Cancer Res; 1994 Aug; 54(16):4342-6. PubMed ID: 8044781
[TBL] [Abstract][Full Text] [Related]
29. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.
Dobashi Y; Sugimura H; Sato A; Hirabayashi T; Kanda H; Kitagawa T; Kawaguchi N; Imamura T; Machinami R
Diagn Mol Pathol; 1993 Dec; 2(4):257-63. PubMed ID: 8118603
[TBL] [Abstract][Full Text] [Related]
30. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
31. [Endometrial carcinoma in situ. Morphological and immunohistochemical aspects].
Plămădeală P; Teleman S; Mihailovici MS
Rev Med Chir Soc Med Nat Iasi; 2003; 107(3):654-6. PubMed ID: 14756081
[TBL] [Abstract][Full Text] [Related]
32. Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis.
Riethdorf L; Begemann C; Riethdorf S; Milde-Langosch K; Löning T
Virchows Arch; 1996 Apr; 428(1):47-51. PubMed ID: 8646368
[TBL] [Abstract][Full Text] [Related]
33. Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples.
Hedrum A; Pontén F; Ren Z; Lundeberg J; Pontén J; Uhlén M
Biotechniques; 1994 Jul; 17(1):118-9, 122-4, 126-9. PubMed ID: 7946294
[TBL] [Abstract][Full Text] [Related]
34. Clinical response to fluorouracil and p53.
Augenlicht LH; Wadler S; Arango D
N Engl J Med; 2001 Oct; 345(14):1065-6. PubMed ID: 11586966
[No Abstract] [Full Text] [Related]
35. Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens.
Plotkin A; Kuzeljevic B; De Villa V; Thompson EF; Gilks CB; Clarke BA; Köbel M; McAlpine JN
Int J Gynecol Pathol; 2020 Nov; 39(6):537-545. PubMed ID: 32281774
[TBL] [Abstract][Full Text] [Related]
36. Cytologic application of p53 overexpression using immunocytochemistry and confocal laser scanning microscopy.
Sato S; Ito K; Jiko K; Konno R; Yajima A; Sasano H
Acta Cytol; 1998; 42(2):342-5. PubMed ID: 9568133
[TBL] [Abstract][Full Text] [Related]
37. p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Kommoss FKF; Jamieson A; McAlpine JN; Gilks CB
Am J Surg Pathol; 2024 Mar; 48(3):373. PubMed ID: 38126250
[No Abstract] [Full Text] [Related]
38. In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis?
Sakamoto I; Kagami K; Nozaki T; Hirotsu Y; Amemiya K; Oyama T; Omata M
Am J Surg Pathol; 2024 Mar; 48(3):374-375. PubMed ID: 38238975
[No Abstract] [Full Text] [Related]
39. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression.
Stavropoulos A; Varras M; Vasilakaki T; Varra VK; Tsavari A; Varra FN; Nonni A; Kavantzas N; Lazaris AC
Oncol Lett; 2019 May; 17(5):4575-4589. PubMed ID: 30944646
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.
Feng YZ; Shiozawa T; Horiuchi A; Shih HC; Miyamoto T; Kashima H; Suzuki A; Nikaido T; Konishi I
Virchows Arch; 2005 Nov; 447(5):816-22. PubMed ID: 16021509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
